GLP-1 drug pipelines
The complete GLP-1 pipeline — approved, Phase 3, and next-gen.
Semaglutide, tirzepatide, retatrutide, oral GLP-1s, and dual/triple incretin agonists. Track sponsor companies, ongoing trials, and upcoming FDA catalysts.
Last updated:Jul 15, 2026Source:ClinicalTrials.gov, FDA.gov, company IRVerified:Manually reviewed by PeptidePlanet research teamData provider:PeptidePlanet Research
Approved & investigational
Every material GLP-1 program from Novo, Lilly, Viking, Structure, Altimmune, and Amgen.
Trial-level detail
NCT identifiers, phase, sponsor, primary completion dates, and outcome measures.
Catalyst calendar
PDUFA dates, expected data readouts, and label expansions in one view.
Newsletter
Get the weekly PeptidePlanet brief.
Free weekly digest of peptide biotech catalysts, trial readouts, and FDA calendar events.
No spam. Unsubscribe anytime.
Frequently asked questions
- What are GLP-1 drugs?
- GLP-1 receptor agonists mimic the incretin hormone glucagon-like peptide-1 to improve glycemic control and induce satiety. Approved examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 agonist.
- Which companies are leading the GLP-1 pipeline?
- Novo Nordisk and Eli Lilly dominate today. Viking Therapeutics, Structure Therapeutics, Altimmune, and Amgen have late-stage or notable early-stage next-generation candidates including oral GLP-1s and multi-agonists.
- What is retatrutide?
- Retatrutide is Eli Lilly's investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently in Phase 3 trials for obesity and related indications.
- How often is the GLP-1 tracker updated?
- Pipeline entries are reviewed weekly against ClinicalTrials.gov and company IR releases. Every peptide profile shows a last-updated date and links to primary sources.